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Abstract: Tauopathies are characterized by accumulation of filamentous tau aggregates. These aggregates can be 
recapitulated in transfectant M1C overproducing wild-type human brain tau 4R0N via the tetracycline off (TetOff) 
inducible expression mechanism. To determine the contribution of proteasomes to tau degradation and 
aggregation, we exposed M1C cells to epoxomicin (Epx; 2-50 nM) or MG132 (0.5 μM) on the 3rd or 4th day of a 5-
day TetOff induction and demonstrated a reduction of proteasomal activity. Cultures treated with 2 nM Exp 
showed accumulation of full-length tau without affecting ubiquitin and β-catenin immunoblotting profiles. In 
contrast, cells treated with 10, 50 nM Epx or MG132 displayed changes in ubiquitin or β-catenin immunoblotting 
profiles and extensive tau degradation/truncation. The increase of tau degradation/truncation was accompanied 
with accumulation of oligomers and sarkosyl-insoluble aggregates of tau, augmented thioflavin-binding and 
activation of caspases and calpains. Truncated, oligomeric and sarkosyl-insoluble tau derivatives appeared with 
caspase-specific cleavage and their production was diminished when pretreated with a pan-caspase inhibitor. The 
results demonstrate (i) a dose-dependent, opposite effect of proteasome inhibition on tau processing, (ii) the 
participation of proteasome-dependent, ubiquitination-independent mechanisms in tau degradation and 
aggregation, and (iii) the promotion of tau aggregation by caspase-mediated tau degradation/truncation. 
Key Words: tau degradation and aggregation, inducible transfectant, cell culture, proteasomal inhibition, caspase, 
calpain 
 
Introduction 
 
Accumulation of microtubule-associated 
protein tau to form filamentous inclusions in 
the central nervous system is a pathologic 
hallmark that characterizes several 
neurodegenerative disorders, including 
Alzheimer’s disease (AD), progressive 
supranuclear palsy, corticobasal degeneration, 
frontotemporal dementia with parkinsonism 
linked to chromosome 17 and Niemann-Pick 
disease type C [1]. When incorporated into 
inclusion, tau is extensively phosphorylated as 
detected in humans and animal models at 
early stages of tauopathies [2]. According to in 
vitro studies, assembly of filamentous 
aggregates requires a critical concentration of 
tau and involves nucleation, oligomerization 
and elongation [3]. The process can be 
accelerated by tau mutation, removal of the 
carboxyl-terminus of tau or in the presence of 
inducers (e.g. heparin, polyunsaturated fatty 
acids) [4-8]. Phosphorylated tau was 
demonstrated to be more resistant to 
proteolysis and less able to bind and promote 
microtubule assembly [9]. In vitro studies have 
also reported that filamentous tau isolated 
from tauopathy brains or assembled in vitro 
are inhibitory to proteasomes. Moreover, AD 
brains were shown to display lower 
proteasome activity than that of their age-
matched controls, even though their level of 
proteasome subunits was not affected [10, 
11]. 
 
It has been documented that tau protein can 
be degraded in vitro by caspase [12-14], 
calpain [15-17], cathepsin D [18-20] and 
proteasomes [21-22]. Treatment of tau-
expressing cells with drugs that are capable of 
perturbing calcium homeostasis was 
demonstrated to cause tau degradation [23]. 
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However, exposing cultured cells expressing 
endogenous or exogenous tau to a 
proteasome inhibitor resulted in tau 
degradation [24, 25], tau accumulation [21] or 
failed to alter tau levels altogether [26]. In one 
study, lactacystin treatment of a stable tau 
transfectant derived from SH-SY5Y cells was 
shown to suppress tau degradation without 
accumulation of ubiquitinated tau [21]. 
Moreover, incubation of recombinant tau with 
20S proteasomes resulted in tau degradation, 
suggesting a ubiquitin-independent pathway 
for tau processing [21]. Other studies using 
cell cultures that were co-transfected with tau 
and ubiquitin or E3 ubiquitin ligase CHIP 
emphasized preferential degradation of 
phosphorylated tau by an ubiquitin-, 
proteasome-dependent mechanism [27]. It 
was reported recently that overexpression of 
CHIP in rat hippocampus led to increased 
degradation of both phosphorylated and non-
phosphorylated tau [28]. CHIP knockout mice 
were shown to have increased level of 
phosphorylated and non-phosphorylated tau 
[29]. Such mice were reported in one study to 
cause a slight increase of SDS-insoluble tau 
[30], but in other studies to elevate the level of 
phosphorylated tau without any impact on tau 
solubility [29]. Treatment of cell cultures 
overexpressing tau with a HSP90 inhibitor 
resulted in proteasome-mediated clearance of 
tau species phosphorylated at proline-directed 
Ser/Thr sites, but not those phosphorylated at 
S262/S356 [31]. 
 
Although aggregated tau derived from AD 
brains was shown to inhibit proteasomal 
activity in vitro [32], whether or not 
proteasomal inhibition per se plays a role in 
tau aggregation remains a question. Equally 
unknown is whether ubiquitin-independent, 
proteasome-dependent and ubiquitin-, 
proteasome-dependent pathways work in 
concert to maintain the level of tau in situ/in 
vivo. To address these issues we used 
transfectant M1C that overexpresses human 
4R0N tau via TetOff inducible mechanism. The 
M1C transfectant is derived from human 
neuroblastoma BE(2)-M17D cells. We have 
previously shown that, after the TetOff 
induction of tau expression for 5 to 7 days, 
these cells accumulate a minute amount of 
sarkosyl-insoluble high-molecular-weight 
(HMW) tau aggregates and oligomeric tau of 
70 kDa consisting of truncated tau species [33, 
34]. A portion of the 70 kDa and nearly all of 
the HMW derivatives disappear to give rise to 
smaller species upon reduction by beta-
mercaptoethanol, suggesting that formation of 
such tau derivatives involves at least in part 
disulfide-crosslink of tau fragments that are 
truncated at the carboxyl-terminus. We also 
showed that autophagic-lysosomal 
perturbation of M1C cells led to increased tau 
oligomers (70 kDa and HMW), increased 
thioflavin binding and aggregation of 
filamentous tau [35]. In the present study, we 
studied the impact of proteasomal inhibition 
on tau degradation/truncation and assembly. 
 
Materials and Methods 
 
Materials 
 
Tissue culture wares were obtained from BD 
Biosciences (Franklin Lakes, NJ). Glass 
coverslips were from Bellco Glass, Inc. 
(Vineland, NJ). Proteasome inhibitors, MG132 
and Lactacystin (0-2 μM) were from 
Calbiochem (San Diego, CA), and epoxomicin 
(Epx) was from Boston Biochem (Cambridge, 
MA). Pan-caspase inhibitor (Z-VAD-FMK) and 
fluorogenic substrate for caspase 3 (substrate 
II) or calpain I substrate [H-K(FAM)-EVY-GMMK 
(DABCYL)-OH] were purchased from 
Calbiochem. Fluorogenic substrate Suc-LLVY-
AMC (Biomol, Plymouth Meeting, PA) was used 
to assay chymotrypsin (chy)-like activity. Other 
chemicals were from Sigma (St. Louis, MO) 
unless indicated otherwise. 
 
Antibodies 
 
The location of epitopes recognized by 
different anti-tau antibodies used in the 
present study is illustrated in Figure 1. These 
antibodies are well characterized and used in 
a number of previous studies (14, 33, 36, 37). 
Monoclonal antibodies to β-catenin (9G10), 
spectrin, calpastatin and glyceraldehydes 3-
phosphate dehydrogenase (GAPDH) were 
obtained from BD Biosciences, Chemicon 
(Temecula, CA), Sigma, and Covance Research 
Products, Inc. (Berkeley, CA), respectively. 
Polyclonal antibodies to cleaved-caspase3, 
caspase 3 or calpain I were form Cell Signaling 
(Danvers, MA). Antibodies were used at the 
following dilutions: P44 (1:5,000), E1 
(1:2,500), Tau 46 (1:5,000), PHF-1 (1:200), 
CP13 (1:200), AT180 (1:200), AT270 (1:400), 
anti-β-catenin (1:500), anti-spectrin (1:1,000), 
anti-cleaved caspase3 (1:500), anti-caspase 3 
(1:500), anti-calpastatin (1:250), anti-calpain I 
(1:250) and anti-GAPDH (1:5,000). 
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Figure 1  Schematic representation of 4R0N tau 
and epitope map for different tau antibodies. 
 
 
Cell Culture 
 
Transfectant M1C derived from human 
neuroblastoma BE(2)-M17D cells [33] 
expresses wild-type human tau isoform 4R0N 
via TetOff inducible expression mechanism 
and accumulates filamentous tau after 
chloroquine treatment [35]. M1C cells were 
seeded at 2 x 106 cells/plate in Dulbecco’s 
modified Eagle’s medium supplemented with 
10% fetal bovine serum, G418 (400 μg/ml; 
Life Technologies, Gaithersburg, MD), Tet (2 
μg/ml), puromycin (1 μg/ml), zeocin (100 
μg/ml) and hygromycin (100 μg/ml). Twenty 
four hours later, tau expression was elicited by 
replacing the spent medium with fresh 
medium containing 1 ng/ml Tet. Replica 
cultures were exposed to proteasomal 
inhibitors [epoxomicin (Epx), MG132] or 
staurosporine (Sigma) on days 3 or 4 of a 5-
day TetOff induction. Cells were harvested at 
the end of such tau induction. Others were 
treated with Z-VAD-FMK (20 μM, Calbiochem) 
3 hrs before Epx incubation. 
 
Fractionation of Cell Lysates 
 
M1C cells were harvested and homogenized in 
Tris buffer containing protease and 
phosphatase inhibitors (30 mM β-
glycerophosphate, 30 mM sodium fluoride, 
1mM phenylmethylsulfonyl fluoride, 1mM 
EDTA and 1mM EGTA). The homogenate was 
centrifuged at 180g for 15 min to derive cell 
lysate. A portion of the lysate was further 
fractionated based on its solubility in Tris 
buffer or 2% sarkosyl to generate SN1, SN2 
and S/P fractions as reported previously [33, 
36]. The SN1 fraction is supernatant derived 
from centrifugation of lysate at 150,000g for 
15 min at 4°C. The pellet was re-suspended in 
a buffer containing 0.8 M NaCl, 10% sucrose, 
10 mM Tris/HCl, pH 7.4, 1 mM EGTA, 1 mM 
PMSF and 1% sarkosyl and centrifuged at 
150,000g for 15 min to yield supernatant 
(SN2) and sarkosyl-insoluble (S/P) pellet. All of 
the supernatants or the sarkosyl-insoluble 
pellet re-suspended in Tris buffer were used 
immediately for immunoblotting and enzymatic 
assay or stored at -80°C. 
 
Western Blotting 
 
Cell lysates or fractionated preparations were 
mixed with Laemmli sample buffer with or 
without 1% β-mercaptoethanol (βME). Protein 
concentration of cell lysates was determined 
using the Bradford assay. Samples containing 
the same amount of protein (8-12 μg, 
corresponding to 0.8-1.2 x 105 cells per lane), 
were resolved by 10% SDS-polyacrylamide gel 
electrophoresis and subsequently transferred 
onto nitrocellulose membrane for 
immunoblotting using antibodies to tau or 
other proteins. The intensity of 
immunoreactivity was quantified by 
densitometry and analyzed using the MCID 
software (Imaging Research Inc., Ontario, 
Canada). 
 
Proteasome Activity Assay 
 
We used cell lysates containing 50 μg protein 
to assay proteasome activity. Samples in a 
reaction buffer (50 μl/sample) containing, 50 
mM HEPES (pH 7.5), 5 mM MgCl2, 150 mM 
NaCl, 20% glycerol, 5 mM sodium 
pyrophosphate, 30 mM β-glycerophosphate, 
30 mM sodium fluoride, and a cocktail of 
protease inhibitors (Sigma) were placed in a 
96 well plate. They were mixed with 100 μM 
Suc-LLVY-AMC fluorogenic substrate for chy-
like activity. The reaction mixtures were 
incubated at 37ºC for 60 min in the dark and 
the fluorescence signals were measured using 
excitation/emission wavelengths at 360 
nm/460 nm and 335 nm/410 nm to assess 
chy-/try-like activity in a SpectraMax M2 
microplate reader (Molecular Devices, 
Sunnyvale, CA). Enzyme specific signals were 
obtained by subtraction of signals derived 
from lysates mixed with proteasomal inhibitor. 
 
Thioflavin S-binding Assay 
 
The sarkosyl-insoluble preparations were re-
suspended in Tris buffer containing 10 µM 
thioflavin S for 20 min and the fluorescence 
signal was measured with a Cary Eclipse 
fluorospectrophotometer (Varian, Walnut 
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Figure 2  Dose-dependent impacts of proteasome 
inhibition on tau processing. M1C cells were 
subjected to a 5-day TetOff induction plus exposure 
to epoxomicin (Epx) at 2 or 10 nM for 2 days or at 
50 nM for 1 day or to 0.5 μM MG132 for a day 
before such induction ended. Cultures treated with 
DMSO served as vehicle control (Epx 0). Cell lysates 
were immunoblotted with antibody P44 (top panel) 
and reprobed with antibody Tau46 (mid-panel). 
Replica blot was probed with GAPDH antibody to 
verify loading (bottom panel). In the 2 nM Epx-
treated, tau species of 62, 54 and 52 kDa 
displayed P44, Tau46 and E1 (data not shown) 
immunoreactivities, suggesting that they are intact 
tau with different extents of posttranslational 
modification. Based on Tau46 immunoblotting, the 
52-kDa (arrowhead) was the most abundant 
followed by 54 (arrowhead) and 62 kDa (arrow). In 
contrast, in vehicle-treated cells, the 62-kDa was 
the most abundant followed by 52 and 54 kDa 
species. In cultures exposed to Epx at higher 
concentrations or to MG132 Tau46-positive tau 
species were reduced or not detectable, but P44-
positve tau species were observed, indicating most 
of these tau are carboxyl-terminally truncated. 
 
 
Creek, CA) using excitation at 440 nm and 
emission at 460-600 nm as described 
previously [33, 35]. All measurements were 
performed in triplicates from three 
experiments. 
 
Results 
 
Dose-dependent Impacts of Proteasome 
Inhibition on tau Processing 
 
We have previously demonstrated that, after 5 
days of TetOff induction, M1C cells 
accumulate derivatives of 4R0N tau that are 
not found in their non-induced counterparts 
[33-35, 38]. Without TetOff induction the level 
of endogenous tau in M1C cells is not 
detectable by Western blotting at the sample 
loading we used. 
 
In the present study, exposure of M1C cells to 
2 nM Epx during the last 3rd and 5th day of 
TetOff induction using 1ng/ml Tet was 
demonstrated to increase the level of at least 
3 exogenous tau species of 52-62 kDa (Figure 
1) as compared to their vehicle control (arrow 
and arrowhead, compare lanes 2 and 1 in 
Figure 2). These bands reacted with antibodies 
that are specific to the mid-region (P44), the 
carboxyl-end (Tau46) (Figure 2) and the amino 
terminus (E1 or Tau12, data not shown) of tau, 
suggesting that they are intact tau species 
exhibiting different states of posttranslational 
modifications. Tau species smaller than 52 
kDa were detected in the 2 nM Epx treated 
and vehicle control. Because intact 
recombinant 4R0N human tau has an 
apparent molecular weight of 52 kDa, 
molecules smaller than 52 kDa are degraded 
derivatives. Quantitative analysis of P44 and 
Tau46 immunoreactivities indicates that, 
compared to the vehicle control, the level of 
62 kDa tau increased to 400% and 200%, 
respectively, following the incubation with 2 
nM Epx (Figure 2). In contrast, exposure of 
their sibling cultures to the same drug at 10 
nM or 50 nM) led to a decrease in the level of 
P44-positive 52-62 kDa species but an 
increase in that of P44-positive ~50 kDa tau 
(Figure 2). The low-molecular-weight tau (<50 
kDa) displayed P44, but not Tau46 
immunoreactivity, indicating that they are 
carboxyl-terminally truncated. A similar tau 
profile was also observed with replica cultures 
following their treatment with proteasome 
inhibitors MG132 (0.5 μM) (Figure 2) and 
lactacystin (0.5, 1 and 2 μM; data not shown). 
 
Proteasome-dependent and Ubiquitination-
independent tau Processing 
 
Because treating cells with 2 nM Epx gave rise 
to tau profile that is different from what can be 
obtained with higher doses (10 or 50 nM), it is 
important to demonstrate the impact of Epx 
treatment (2, 10 or 50 nM) on proteasomal 
activity. We used fluorogenic substrates and 
cell lysate prepared from the treated cultures 
and vehicle control for measurement of chy-
like activity (Figure 3). After exposing cells to 2 
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Figure 3  Dose-dependent inhibition of proteasomal 
activity. Fluorogenic assays were used to assess 
chymotrypsin-like (chy-like) activity. Cultures with 
Epx exposure exhibited lower proteasome activity 
than their vehicle-treated counterparts, and the 
extent of reduction depended on the drug 
concentration. The chy-like activity of the Epx-
treated (at 2 nM) was 70% of that found with its 
vehicle control verifying proteasomal inhibition of 
such drug exposure (p <0.05, Student’s t test; n=3). 
Y axis showed fluorescence intensity in arbitrary 
units. 
 
 
nM Exp, chy-like activity was significantly 
reduced to 70% of that found in cells treated 
with the vehicle only (p<0.05., Student’s t test; 
n=3). A further reduction in such activity was 
noted in the cells treated with higher 
concentration of Epx or MG132 (data not 
shown). 
 
To determine if Epx treatment and the 
resulting decrease in proteasome activity led 
to accumulation of ubiquitinated proteins, we 
immunoblotted the cell lysates using 
antibodies to ubiquitin. Unlike the change in 
tau levels observed following 2 nM Epx 
treatment, no change in the ubiquitin profile 
was observed between cells treated with 2 nM 
Epx and vehicle control (Figure 4A). In contrast, 
a substantial increase in ubiquitin 
immunoreactivity was evident in samples 
exposed to higher concentrations of Epx (10 
and 50 nM). To verify that 2 nM Epx treatment 
has no impact on tau ubiquitination, we 
performed immunoprecipitation studies. Cell 
lysates were incubated with anti-tau 
antibodies before probing the resulting 
immunoprecipitate with ubiquitin antibodies. 
There was no difference in the ubiquitin 
immunoprofile between cells exposed to 0 or 2 
nM Epx (data not shown). Together, our results 
suggest that tau accumulation in the 2 nM 
Epx-treated cells is proteasome-dependent 
and ubiquitin-independent. 
 
Dose-dependent Effect of Proteasomal 
Inhibitors on Caspase and Calpain Activation 
 
To test if caspases and/or calpain play a role 
in the tau degradation/truncation when the 
cells were treated with high concentrations of 
proteasome inhibitors, we examined levels of 
β-catenin (a substrate of caspase), spectrin (a 
substrate of calpain and caspase), caspase 3, 
calpain, and calpastatin (endogenous calpain 
inhibitor) by Western blot analysis (Figures 4B, 
C and E). There was very little difference in the 
expression level of these proteins in cells 
treated with 2 nM Epx compared to the vehicle 
control. In contrast, increased degradation of 
β-catenin (Figure 4B) and spectrin (Figure 4C) 
was observed in cells exposed to higher doses 
of Epx (10 and 50 nM) or 0.5 μM MG132. For 
instance, the level of intact spectrin (250 kDa) 
decreased, while that of spectrin degradation 
products increased. Based on previous studies 
[39-41], these changes probably reflect 
degradation of β-catenin by caspases and 
degradation of spectrin by calpains and/or 
caspases. This was supported by subsequent 
immunoblotting data in which cleaved-caspase 
3 (active form) was detectable in the cells 
treated with Epx at 10 nM or higher 
concentration (Figure 4D), suggesting 
apoptotic activity. It is also consistent with the 
results from previous studies in which 
exposure of neurons or non-neuronal cells to a 
proteasomal inhibitor led to apoptosis [42-46]. 
 
Calpain immunoblotting showed no difference 
between the vehicle control and the Epx (50 
nM)- or MG132 (0.5 μM)-treated cells (Figure 
4E). However, the drug-treated clearly 
displayed less calpastatin immunoreactivity 
(Figure 4E). Since calpastatin is a substrate of 
caspase-3, the degradation of calpastatin may 
have been caused by caspase-3 activation 
[47]. Given that calpastatin is an endogenous 
inhibitor of calpain, the reduction in 
calpastatin indicates that calpain is likely 
activated in the treated cells. Together, these 
results suggest that tau degradation from the 
exposure to proteasome inhibitors (i.e. > 10 
nM Epx) involves activation of calpain and/or 
caspases. 
 
Caspase Activation and tau Degradation 
 
To determine whether caspase activation plays 
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Figure 4  Impact of proteasome inhibition on the integrity of various proteins. Immunoblotting of lysates derived 
from the TetOff induced cells, with or without the exposure to proteasome inhibitors, using antibodies to (A) 
ubiquitin, (B) β-catenin, (C) spectrin, (D) caspase-3, and (E) calpain I and calpastatin. Exposure to 2 nM Epx had 
very little impact on the profile and immunoreactivity of the aforementioned proteins studied (data for calpain I 
and calpastatin not shown). In contrast, exposure to more concentrated Epx (>10 nM) or 0.5 μM MG132 caused 
an increase in ubiquitin and cleaved caspase-3 immunoreactivities, a decrease in calpastatin immunoreactivity 
and altered β-catenin and spectrin profiles without affecting the level of calpain I. 
 
 
a role in tau degradation caused by 
proteasome inhibition, we treated the M1C 
cultures to 50 nM Epx in the absence or 
presence of the pan-caspase inhibitor, Z-VAD-
FMK. Cultures exposed to Z-VAD-FMK and Epx 
contained more intact tau (i.e. >52-kDa tau 
immunopositive for P44 and Tau46) than 
those treated with Epx alone (Figure 5A). 
Pretreatment with the caspase inhibitor also 
caused a reduction in the amount of cleaved-
caspase 3 (Figure 5B), supporting the 
involvement of caspase in tau cleavage. 
Differential Impacts of Proteasome Inhibition 
on Accumulation of Phosphorylated and Non-
phosphorylated tau 
 
Previous studies have reported that 
phosphorylated tau is more resistant than its 
non-phosphorylated counterpart to proteolytic 
degradation [23], and that distinct chaperons 
may be involved in degrading tau 
phosphorylated at different sites [31]. To study 
the impact of proteasome inhibition on 
phosphorylated tau, we examined levels of 
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Figure 5  Caspase-mediated tau degradation from proteasome inhibition. M1C cultures were induced to express 
tau via TetOff induction for 5 days and treated (1) with vehicle (DMSO), (2) with 50 nM Epx during the last day of 
induction, or (3) treated with a pan-caspase inhibitor Z-VAD-FMK (20 μM), 3 hrs before Epx (50 nM) incubation. 
Cell lysates were probed with (A) antibodies P44, Tau46 and (B) antibodies to cleaved caspase-3. As was 
illustrated in Figure 2, P44 detected in the 50 nM Epx-treated cells mostly truncated tau species that lack Tau46 
immunoreactivity (lanes 2). Such loss of Tau46 immunoreactivity was, however, absent in the Exp-treated cells 
that were pretreated with Z-VAD-FMK (lane 3). The level of cleaved caspase-3 was higher in the Exp-treated than 
its vehicle control, and such change was prevented by caspase inhibition (B, compare lanes 2 and 3). 
 
 
 
Figure 6  Impact of proteasome inhibition on processing of phosphorylated tau. Lysates of M1C cultures, with or 
without proteasome inhibition, were immunoblotted using phospho-tau antibodies to 6 epitopes (see Figure 1) 
collectively, and reprobed subsequently using GAPDH to verify sample loading. In the cultures treated with 2 nM 
Epx, antibodies PHF-1, and AT180 detected the 62-kDa with its intensity higher than that of the vehicle control, 
whereas A270 immunoreactivity appeared reduced and CP13 immunoreactivity was affected inconsistently. 
Fewer phospho-tau bands were present in the samples treated with 50 nM Epx, and most of them were around 
50 kDa. 
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phosphorylated tau in the lysates obtained 
from M1C cell following Epx treatment using 
antibodies PHF-1, CP13, AT180 and AT270 
which recognize distinct phosphorylated 
epitopes (Figure 6). When compared to the 
vehicle control, the level of PHF-1 or AT180 
immunoreactivity in the 2 nM Epx-treated cells 
increased consistently. In contrast, AT270 
immunoreactivity tended to decrease and 
CP13 immunoreactivity was not consistently 
affected, suggesting that tau phosphorylated 
at some sites are more resistant than others 
to proteasomal degradation. Treatment with 
10 nM Epx reduced the amount of 
phosphorylated 62 kDa tau, and 
phosphorylated tau decreased further when 
exposed to Epx at even higher concentrations. 
 
To determine if  proteasomal inhibition 
preferentially causes accumulation of intact 
tau species that are less or not 
phosphorylated, we compared the relative 
amount of Tau46-immunoreactive 62, 54 and 
52 kDa (Figure 1) tau in cultures treated with 
2 nM Epx and their vehicle control. The ratio of 
62, 54 and 52 kDa tau species in the vehicle 
control is 1:0.2:0.7 whereas that in the 2 nM 
Epx-treated is 1:1.9: 2.7. Such increase in the 
proportion of 52 and 54 kDa tau probably 
reflects accumulation of the less 
phosphorylated tau species, since 
electrophoretic mobility of tau is known to be 
retarded by phosphorylation. Our results are in 
agreement with previous reports in which 
phosphorylated tau was shown to be less 
susceptible to proteolysis [23]. 
 
Proteasomal Inhibition-induced tau 
Oligomerization and Aggregate Assembly 
 
We showed previously that a 5-7 day TetOff 
induction at 1 ng/ml Tet leads to formation of 
high-molecular- weight aggregates via disulfide 
cross-linking of C-end truncated tau species, 
including 70-kDa tau oligomers and a small 
quantity of sarkosyl-insoluble tau in M1C cells 
[33, 35]. We also showed that increased 
production of 70 kDa tau oligomer is 
associated with increased accumulation of 
high-molecular-weight tau [33, 35]. However, it 
is uncertain whether formation of tau 
aggregates involves incorporation of caspase-
cleaved tau fragments. We examined this 
issue by Western blot analysis using lysates 
(see Figure 7) from cultures with and without 
exposure to Epx and their fractionated 
preparations (see Figure 8). 
 
 
 
Figure 7  Accumulation of the 70-kDa tau from proteasome inhibition or staurosporine treatment. M1C cells, 
induced to express tau for 5 days via TetOff induction using 1 ng/ml Tet supplementation were exposed to Epx 
(50 nM) and staurosporine (100 nM) for 1 day and 12 hours, respectively, before the end of such induction or to 
DMSO throughout the induction. Cell lysates were probed with antibody P44, Tau 46 and GAPDH. (A) The 70-kDa 
species (asterisk), not readily discernible in Figure 2, appeared after prolonged exposure. They displayed P44 but 
not Tau46 immunoreactivity. The amount of the 70-kDa tau did not change in the M1C cells after 2 nM Epx 
treatment, but increased in those exposed to higher concentrations of Epx or with MG132. (B) Staurosporine 
treatment (lane 5) caused an increase of the 70-kDa and smaller sizes tau species as that observed in the Epx 
treated (lane 3). The increase of 70-kDa tau was less in the staurosporine-treated. Cells without TetOff induction 
were included to show the impact of induction on tau expression (lane 2) and recombinant 4R0N tau was 
included as a reference (lane 1). 
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Figure 8  Epoxomicin exposure caused accumulation of sarkosyl-insoluble tau aggregates and increase in 
thioflavin binding. Lysates (Ly) from M1C cells with or without 50 nM Exp treatment were fractionated to derive 
SN1, SN2 and S/P fractions. A portion of each sample was analyzed by Western blotting in the presence or 
absence of β-mercaptoethanol (βME) using antibodies P44 (A and B), Tau C3 (C) and Tau46 (data not shown). (D) 
Thioflavin-S binding assay of the S/P preparations derived from Exp- or DMSO-treated cells. The 70-kDa tau 
(asterisk) did not react with Tau C3 or Tau 46. High-molecular-weight tau aggregates (bracket) were evident in the 
S/P fraction. The level of such aggregates was higher in the Epx-treated. Moreover, the presence of Tau C3-
positive tau aggregates in the S/P fraction distinguishes the Epx-treated samples from their vehicle control. 
Samples processed under the reducing (+βME) condition lacked high-molecular-weight tau aggregates and 
exhibited less tau oligomers of 70~220-kDa, when compared to their non-reduced counterparts. Enhanced 
thioflavin-S binding was evident in the Epx-treated but not in its vehicle control (D). 
 
 
As expected from previous studies [33, 35], 
the 70-kDa tau was detectable in small 
amount in vehicle treated cultures. The 70-
kDa tau was immunopositive for P44 but not 
Tau46, and its detection required long 
exposure time for image capturing or 
increased sample loading (asterisks, Figure 7A 
is derived from Figure 2 after extended 
development). The amount of the 70-kDa tau 
was comparable between M1C cells treated 
with vehicle and those treated with 2 nM Epx 
(Figure 7A), but increased in the cells treated 
with higher concentrations of Epx. Since 
increased levels of cleaved-caspase were 
observed in cultures treated with >10 nM Epx 
(Figure 4D), this raised the possibility that 
truncated-tau derived from caspase cleavage 
may contribute to the assembly of the 70-kDa 
species. We tested this possibility by treating 
the M1C cultures with staurosporine, an 
inducer of apoptosis (lane 5, Figure 7B). 
Although the staurosporine-treated cultures 
contained more abundant 70-kDa tau than the 
vehicle control (lane 4, Figure 7B) and they 
displayed a tau profile resembling that of 50 
nM Epx-treated cells (lane 3, Figure 7B), the 
70-kDa tau was not recognized by Tau C3, an 
antibody specific for tau cleaved by caspase at 
D421 (data not shown). 
 
To study the impact of proteasome inhibition 
on accumulation of aggregated tau, we used 
M1C cultures treated with 50 nM Epx (Figure 
8), since such samples showed increased level 
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of 70 kDa tau oligomers. Lysates derived from 
these cells were separated into three fractions 
(SN1, SN2, S/P) based on their solubility in 
buffer or sarkosyl. Fractions from the vehicle- 
or Epx-treated cells were analyzed under non-
reducing (-βME) or reducing (+βME) conditions 
and compared for their reactivity to antibodies 
P44 (Figure 8A and B) and Tau C3 (Figure 8B). 
Under non-reducing condition, more P44- and 
Tau C3-positive sarkosyl-insoluble (S/P) tau 
appeared in samples from the Epx-treated 
cultures than those from vehicle controls. 
Some of the insoluble tau species were too 
large to be separated by SDS-polyacrylamide 
gel (bracket, Figure 8). These tau aggregates 
and oligomeric tau species, except for the 70-
kDa tau, were not observed under reducing 
condition (Figure 8B, +βME, P44). The 70-kDa 
tau was only partially sensitive to βME. The 
results are in agreement with previous report 
indicating the involvement of disulfide cross-
link in oligomeric tau production [33, 35]. It is 
worth noting that high-molecular-weight 
insoluble aggregates display Tau C3 
immunoreactivity, whereas the 70-kDa 
oligomeric tau does not (Figure 8C). The 
increase of the 70-kDa species as a 
consequence of proteasome inhibition, 
therefore, is likely due to the assembly tau 
fragments that were cleaved by proteases 
other than caspases. One such candidate 
protease is calpain I, since the cultures treated 
with 50 nM Epx or 0.5 μM MG132 showed 
calpain activation (Figure 4). Our data, 
however, do not rule out the possibility that 
caspase-cleaved tau may be degraded further 
by calpains or other proteases to generate 
fragments from which the 70-kDa oligomer is 
assembled. 
 
The possibility that sarkosyl-insoluble samples 
contain tau with altered conformation is 
substantiated by their augmented thioflavin-
binding, which reflects transformation to β-
sheet structure. Such enhanced affinity for 
thioflavin S was evident in the 50 nM Epx-
treated compared to their vehicle-treated 
controls (Figure 8D, thioflavin binding). The 
integrated fluorescence signals for the vehicle 
control and the Epx-treated samples are 
1085.8 + 168.7, and 1591.1 + 96.3 in 
arbitrary unit, respectively (Student’s t test, 
p<0.05, n=3). 
 
Discussion 
 
There is ample evidence indicating the 
ubiquitin-proteasome system is compromised 
in AD brains. However, it remains uncertain 
whether such abnormality causes 
accumulation of monomeric tau leading to its 
assembly to form aggregates or is a result of 
interactions between aggregated tau and 
proteasomes. While some cell-based studies 
showed that proteasomal inhibition decreases 
turnover of wild-type tau, others showed that it 
accelerated tau turnover [21, 22, 24-26]. The 
discrepancy could be due to variations in the 
type proteasome inhibitor and/or its 
concentration used in different studies. 
Moreover, these studies did not investigate 
whether proteasomal perturbation leads to 
production/accumulation of tau aggregates. 
 
In the present studies, we treated M1C cells 
that produces wild-type human tau with 
different concentrations of proteasome 
inhibitor Epx and analyzed the tau profile of 
cell lysates. We demonstrated that exposure to 
2, 10 or 50 nM Epx results in a decrease in 
chymotrypsin-like activity in a dose-dependent 
manner, ranging from 30 to 70% reduction. 
We also demonstrated that tau degradation in 
M1C cells was inhibited by the 2 nM Epx 
treatment and accelerated by higher dosages 
of Epx. Such enhanced tau degradation was 
accompanied with activation of caspase-3 and 
decrease of calpain I inhibitor (i.e. calpastatin), 
and this was prevented by pretreatment with a 
pan caspase inhibitor. In addition, Tau C3-
positive tau fragments were demonstrated in 
the Epx (50 nM)- or staurosporine-treated cells, 
but not in those pretreated for caspase 
inhibition. The tau degradation from Exp 
treatment, therefore, is likely to involve 
caspase-3. It may also involve calpain I as 
suggested by the decrease of its endogenous 
inhibitor calpastatin. Lysosomal proteases 
appears to play very little role in such tau 
degradation, since we have previously shown 
that exposing the M1C cells to chloroquine 
results in a substantial accumulation of full-
length tau [35]. It is worth noting that the level 
of 70 kDa tau oligomers was not affected by 2 
nM Exp treatment as was demonstrated in 
cultures treated with chloroquine [35]. 
 
The 70-kDa tau appeared with higher 
abundance in cultures exposed to 50 nM Exp 
than that of those treated with lower doses of 
Epx or their vehicle control. Our analysis of 
fractionated preparations showed more 
sarkosyl-insoluble tau in the 50 nM Exp-
treated cultures than that of the vehicle 
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control or those treated with 2 nM Exp (data 
not shown). The results are consistent with our 
previous studies in which assembly of high-
molecular-weight, soluble tau oligomers and 
insoluble tau aggregates was shown to 
associate with production of 70 kDa tau [33, 
35]. 
 
We have demonstrated in the present and 
previous studies that the 70-kDa protein is 
partially resistant to reducing agent β-
mercaptoethanol and it contains carboxyl-
terminally cleaved tau [33, 35]. Although the 
cleavage site(s) remains to be determined, it is 
evident from Tau C3 immunoblotting that 
caspase-cleaved tau fragments are absent in 
the 70-kDa protein. Tau C3-positive tau 
fragments, detected in the vehicle control, are 
present in the sarkosyl-insoluble, high-
molecular-weight aggregates produced by the 
Exp-treated cells. This may reflect co-assembly 
of caspase-cleaved fragments with the 70-kDa 
tau or other oligomers. Alternatively, some tau 
aggregates may be produced from self-
assembly of Tau C3-positive fragments. In this 
regard, previous immunocytochemical studies 
revealed that caspase-cleaved tau is present 
in AD brains and that Tau C3 labels only a 
subset of neurofibrillary tangles [48-50]. 
Moreover, a tau antibody to a conformation-
dependent epitope was demonstrated to label 
neurofibrillary tangles differently from what 
conformation-independent antibodies did [49]. 
These studies led to a model proposed for the 
progression of tangle formation that predicts 
incorporation of Tau C3-positive fragments 
subsequent to conformational change of tau to 
acquire Alz50 epitope. 
 
Our finding of increased amount of Tau C3-
positive sarkosyl-insoluble, thioflavin positive 
tau in the cultures exhibiting marked 
proteasome inhibition is consistent with the 
view that proteasomal dysfunction can 
contribute to the assembly and accumulation 
of tau proteins in tauopathies, and that tau 
assembly can be enhanced by its truncation at 
the carboxyl-terminus. It has been reported 
that proteasomes prepared from AD brains 
display significantly lower level of 
chymotrypsin-like activity when compared to 
age- and postmortem-matched controls or 
subjects with mild cognitive impairment (MCI) 
[51]. On average, the chymotrypsin-like activity 
of AD samples is about 28% less than that of 
normal controls or MCI. It is worth noting that 
the extent of reduction found in AD 
preparations is comparable to that 
demonstrated in the M1C cultures treated with 
2 nM Epx, which is about 30 % less than their 
vehicle control. The results of our cell-based 
studies, therefore, suggest that a moderate 
decrease in chymotrypsin activity in AD brain 
may impact the accumulation of intact tau 
more than that of fibrillogenic tau fragments. 
Since most studies of human brain 
proteasomes used subjects at the end-stages 
of AD, it remains unknown whether the 
disease progresses with a gradual decline in 
proteasomal activity and whether the decline 
is much more severe in some individuals than 
others. Regardless, our cell-based studies 
support the possibility that accumulation of 
tau aggregate in tauopathies can be initiated 
by accumulation of carboxyl-terminally 
truncated tau from severe dysfunction of 
proteasomes or by accumulation of full-length 
as a consequence of impaired autophagic-
lysosomal pathway. 
 
In summary, our studies demonstrate that 
exposures of M1C cultures to proteasome 
inhibitors can lead to accumulation or 
degradation/truncation of tau, depending on 
the concentration of inhibitors. It is likely that 
enhanced tau degradation/truncation results 
from caspase and calpain activation, and 
contributes to the augmented assembly of 
oligomers and aggregates containing tau 
cleaved at D421. 
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